Full View

Final study report of andexanet alfa for major bleeding with factor Xa inhibitors

TJ Milling Jr, S Middeldorp, L Xu, B Koch, A Demchuk… - Circulation, 2023 - Am Heart Assoc
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …
被引用次数：84 相关文章

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.

TJ Milling, S Middeldorp, L Xu, B Koch… - …, 2023 - scholarlyworks.beaumont.org
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa)
designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the …

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

T Milling, S Middeldorp, L Xu, B Koch, A Demchuk… - Circulation, 2023 - hal.science
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Final Study Report of Andexanet Alfa for Major Bleeding with Factor Xa Inhibitors

TJ Milling, S Middeldorp, L Xu, B Koch… - …, 2023 - researchinformation.amsterdamumc …
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

JTJ Milling, S Middeldorp, L Xu, B Koch, A Demchuk… - Circulation, 2023 - lirias.kuleuven.be
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa)
designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the …
[PDF] ru.nl

[PDF][PDF] Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

JTJ Milling, S Middeldorp, L Xu, B Koch, AM Demchuk… - 2023 - repository.ubn.ru.nl
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa)
designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the …

Final study report of andexanet alfa for major bleeding with factor Xa inhibitors

TJ Milling, S Middeldorp, L Xu, B Koch… - 2023 - opus.bibliothek.uni-augsburg.de
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa)
designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the …
[PDF] core.ac.uk

[PDF][PDF] Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

JW Eikelboom, P Verhamme, AT Cohen… - Circulation, 2023 - core.ac.uk
BACKGROUND: Andexanet alfa is a modified recombinant inactive factor Xa (FXa)
designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the …

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.

TJ Milling Jr, S Middeldorp, L Xu, B Koch, A Demchuk… - Circulation, 2023 - europepmc.org
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa
inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of …

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

TJ Milling Jr, S Middeldorp, L Xu, B Koch… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …